Recombinant anti-CD4 antibodies for human therapy

Details Recombinant anti-CD4 antibodies for human therapy Recombinant anti-CD4 antibodies for human therapy

2008-03-04

2008-03-04

Yaen, Christopher (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07338658

ABSTRACT:
Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 4978745 (1990-12-01), Schoemaker et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5756096 (1998-05-01), Hanna et al.
patent: 0 451 216 (1991-10-01), None
patent: 0 523 949 (1992-07-01), None
patent: 0 523 949 (1993-01-01), None
patent: 0 682 040 (1995-11-01), None
patent: 1 266 965 (2002-12-01), None
patent: 1 266 965 (2003-01-01), None
patent: WO 88/07089 (1988-09-01), None
patent: 9008198 (1990-07-01), None
patent: WO 90/15152 (1990-12-01), None
patent: WO 94/08619 (1994-04-01), None
Newkirk et al (Arthritis and Rheumatism 1990; 33(6):800-809).
Newman et al (Biotechnology 1992;10(11):1455-1460).
Angal et al (Mol. Immunol. 1993; 30(1):105-108).
Combriato, G., et al., Vλ and Jλ -Cλ gene segments of human immunoglobulin λ light chain locus are separated by 14 kb and rearrange by a deletion mechanism,Eur. J. Immunol. 21:1513-1522 (1991).
Houghton, A., et al., Monoclonal antibodies: potential applications to the treatment of cancer,Seminars in Oncology, 13(2):165-179 (1986).
Hughes-Jones, N., et al., Nucleotide sequences and three-dimensional modelling of the VHand VLdomains of two human monoclonal antibodies specific for the D antigen of the human Rh-blood-group system,Biochem. J. 268:135-140 (1990).
Riechmann, L., et al., Reshaping human antibodies for therapy,Nature 332(6162):323-327 ( Mar. 24, 1988).
Schroeder, H., et al., Early restriction of the human antibody repertoire,Science, New Series, 238(4828):791-793 (Nov. 6, 1987).
Stephens, D.M., et al., Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine,Journal of General Virology, 73:1099-1106 (1992).
Truneh, A., et al., Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants,Cellular Immunology 131:98-108 (1990).
Van Meurs, G.J.E., et al., Production of primate monoclonal antibodies,Journal of Immunologial Methods, 95:123-128 (1986).
Watanabe, M., et al., Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response,Proc. Natl. Acad. Sci. USA, 88:4616-4620 (Jun. 1991).
Jones, P.T. et al., Nature, 321:522, (1986).
Camerini, D. and Seed, B., Cell, 60:747, (1990).
McClure, M.O. et al., Nature 330:487, (1987).
Truneh, A. et al., Cell. Immun., 131:98, (1990).
Nishimura, Y. et al., Cancer Research, 47:999 (1987).
Ward, E.S. et al., Nature, 341:544 (1989).
Camerini, D. and Seed, B., Abstract No. T.C.P. 125, V International Conference on AIDS, p. 587, (1989).
Persson et al., Proc. Natl. Acad. Sci. USA, 88:2432, 1991.
Meek et al., J. Immun., 146:2434, 1991.
Allison et al., J. Immunological Methods, 95:157, 1986.
Ehrlich et al., Hybridoma, vol. 7, No. 4, pp. 385-395, 1988.
Ehrlich et al., Clin. Chem., 34:1681, 1988.
Van Meel et al., J. Immunological Methods, 80:267, 1985.
BS Heteromycloma line, abstract.
Ehrlich et al., Hum. Antibod. Hybridomas, 1990, vol. 1, No. 1.
Ehrlich et al., Hybridoma, vol. 6, No. 2, p. 151-160, 1987.
Herpes Transformation, abstract.
Amoroso et al., J. Immun., 145:3155, 1990.
Huse et al., Science, 246:1275, 1989.
Letvin, et al., Effect of Recombinant Soluble CD4 in Rhesus Monkeys Infected With Simian Immunodeficiency Virus of Macaques, Abstract from the V Int. Conf. on AIDS, 1989, p. 535.
Rosenberg, M. et al.,Biotherapy, “Soluble recombinant CD4—A potential therapeutic agent for HIV infector”, 2:107, (1990).
Riechmann, L. et al.,Nature, “Reshaping human antibodies for therapy”, 332:323-327, (1988).
Houghton, A.N. et al.,Seminars in Oncology, “Monoclonal antibodies potential applications to the treatment of cancer”, 13:165, (1986).
Watanabe, M. et al., Proceedings of the National Academy of Sciences, 88:4616-4620, (1991).
Van Meurz et al. Journal of Immunological Methods (1986) 123.
Morrison Science, vol. 229, 1202 (1985).
Immunology Today 10:253 (1989).
Queen et al., PNAS 8610029 (1989).
Waldmann Science, vol. 252, 1657, (1991).
Hied et al., Genes and cancer (1990) p. 183.
Vopr Virusol, vol. 30, No. 5, issued Oct. 1985, Markova et al., “Monkey B lymphocyte subpopulations transformed by baboon herpes virus in vivo and in tissue cultures”, pp. 549-553.
Harris et al., T.B. Tech., vol. 11, p. 42 (1993).
Truneh et al., “Humoral Response of Cynomolgus Macaques to Human Soluble CD4: Antibody Reactivity Restricted to Xeno-Human Determinants” Cellular Immunology, Nov. 1990, vol. 131, No. 1, pp. 98-108.
Van Meurs et al. “Production of Primate Monoclonal Antibodies” Journal of Immunological Methods, 1986, vol. 95, pp. 123-128.
Schroeder et al. “Early Restriction of the Human Antibody Repertoire” SCIENCE, Nov. 6, 1987, vol. 238, pp. 791-793.
Combriato et al. “V Lambda and J Lambda-C Lambda Gene Segments of the Human Immunoglobulin Lambda Light Chain Locus are Separated by 14 KB and Rearrange by a Deletion Mechanism” European Journal of Immunology, Jun. 1991, vol. 21, pp. 1513-1522.
Hughes-Jones et al. “Nucleotide Sequences and Three-Dimensional Modelling of the VH and VL Domains of Two Human Monoclonal Antibodies Specific for the D Antigen of the Human RH-Blood Group System” The Biochemical Journal, May 15, 1990, vol. 268, No. 1, pp. 135-140.
Stephens et al., “Antibodies are Produced to the Variable Regions of the External Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 in Chimpanzees Infected with the Virus and Baboons Immunized with a Candidate Recombinant Vaccine” The Journal of General Virology, May 1992, vol. 73, No. 5, pp. 1099-1106.
Ren EC (Ann Acad Med Singapore Jan. 1991; 20(1):66-70).
L.J. Cooper, “H Chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate,” J. Immunol., (Abstract), vol. 146 (No. 8), p. 2659-63, (Apr. 15, 1991).
JJ Goronzy, “T and B cell-dependente pathways in rheumatoid arthritis,” Curr Opin Rheumatol., (Abstract), vol. 7 (No. 3), p. 214-221, (May 1995).
Richard O. Williams, “Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis,” Proc. Natl. Acad., Immunology, p. 2762-2766, (Mar. 1994).
Ellison et al., “Genbank locus P01861,” Ig gamma-4chain . . . (Abstract).
Yocum et al., “Immunomodulatory Effect of Primatized IDE-CE9, an Anti-CD4 Monoclonal Antibody, in RA,” (Abstract), (Oct. 1994).
Solinger et al., “Immunological markers of response in a multi-dose protocol 7002 using an immunomodulating, non-depleting primatized anti-CD4 monoclonal antibody in rheumatoid arthritis (RA),” (Abstract), (Jun. 1996).
Kaine et al., “Results of a multi-dose protocol 7002 using an immunomodulating, non-depleting primatized anti-cd4 monoclonal antibody in rheumatoid arthritis (RA),” (Abstract), (Oct. 1995).
Duncan et al., “Localization of the binding site for the human high-affinity Fc receptor on IgG,” (Abstract), (Apr. 1988).
Anderson et al., “A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4,” Clin. Immunol. a

Affiliated with

Also associated with

Rating

Recombinant anti-CD4 antibodies for human therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-CD4 antibodies for human therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-CD4 antibodies for human therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811281